Last reviewed · How we verify

NCT06199440

Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes

Completed Phase 1, PHASE2 Last updated 10 January 2024
What this trial tests

Phase 1, PHASE2 trial testing Group I in Periodontal Diseases in 15 participants. Completed in 30 March 2023.

Timeline
1 June 2022
Primary endpoint
30 March 2023
30 March 2023

Quick facts

Lead sponsorKing Abdulaziz University
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment15
Start date1 June 2022
Primary completion30 March 2023
Estimated completion30 March 2023
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

King Abdulaziz University

Who can join

Adults 25 to 50, any sex, with Periodontal Diseases or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the adjunctive effects of systemic antibiotics used in nonsurgical periodontal treatment (NSPT), compared with NSPT alone, on the periodontal clinical parameters and resistin level in diabetic patients with periodontitis, in order to identify which, one provides an additional effect to non-surgical periodontal therapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Group I

Trials testing the same drug.

Other recruiting trials for Periodontal Diseases

Currently open trials in the same condition.

Other King Abdulaziz University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06199440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing